|
1
|
Anthony PP, Ishak KG, Nayak NC, Poulsen
HE, Scheuer PJ and Sobin LH: The morphology of cirrhosis.
Recommendations on definition, nomenclature, and classification by
a working group sponsored by the World Health Organization. J Clin
Pathol. 31:395–414. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hernandez-Gea V and Friedman SL:
Pathogenesis of liver fibrosis. Annu Rev Pathol. 6:425–456. 2011.
View Article : Google Scholar
|
|
3
|
Gressner AM and Weiskirchen R: Modern
pathogenetic concepts of liver fibrosis suggest stellate cells and
TGF-β as major players and therapeutic targets. J Cell Mol Med.
10:76–99. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Friedman SL: Hepatic stellate cells:
Protean, multifunctional, and enigmatic cells of the liver. Physiol
Rev. 88:125–172. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tacke F and Weiskirchen R: Update on
hepatic stellate cells: Pathogenic role in liver fibrosis and novel
isolation techniques. Expert Rev Gastroenterol Hepatol. 6:67–80.
2012. View Article : Google Scholar
|
|
6
|
Popov Y and Schuppan D: Targeting liver
fibrosis: strategies for development and validation of antifibrotic
therapies. Hepatology. 50:1294–1306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schuppan D and Kim YO: Evolving therapies
for liver fibrosis. J Clin Invest. 123:1887–1901. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nicoletti A, Fagone P, Donzuso G, Mangano
K, Dibilio V, Caponnetto S, Bendtzen K, Zappia M and Nicoletti F:
Parkinson's disease is associated with increased serum levels of
macrophage migration inhibitory factor. Cytokine. 55:165–167. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fagone P, Di Rosa M, Palumbo M, De
Gregorio C, Nicoletti F and Malaguarnera L: Modulation of heat
shock proteins during macrophage differentiation. Inflamm Res.
61:1131–1139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Parkinson H, Sarkans U, Kolesnikov N,
Abeygunawardena N, Burdett T, Dylag M, Emam I, Farne A, Hastings E,
Holloway E, et al: ArrayExpress update - an archive of microarray
and high-throughput sequencing-based functional genomics
experiments. Nucleic Acids Res. 39(Database issue): D1002–D1004.
2011. View Article : Google Scholar :
|
|
11
|
Fagone P, Muthumani K, Mangano K, Magro G,
Meroni PL, Kim JJ, Sardesai NY, Weiner DB and Nicoletti F: VGX-1027
modulates genes involved in lipopolysaccharide-induced Toll-like
receptor 4 activation and in a murine model of systemic lupus
erythematosus. Immunology. 142:594–602. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Amann T, Bataille F, Spruss T, Mühlbauer
M, Gäbele E, Schölmerich J, Kiefer P, Bosserhoff AK and Hellerbrand
C: Activated hepatic stellate cells promote tumorigenicity of
hepatocellular carcinoma. Cancer Sci. 100:646–653. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bissell DM, Wang SS, Jarnagin WR and Roll
FJ: Cell-specific expression of transforming growth factor-beta in
rat liver. Evidence for autocrine regulation of hepatocyte
proliferation. J Clin Invest. 96:447–455. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Coker RK, Laurent GJ, Shahzeidi S, Lympany
PA, du Bois RM, Jeffery PK and McAnulty RJ: Transforming growth
factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast
procollagen pro duction in vitro but are differentially expressed
during bleomycin-induced lung fibrosis. Am J Pathol. 150:981–991.
1997.PubMed/NCBI
|
|
15
|
Watanabe K, Tajino T, Sekiguchi M and
Suzuki T: h-Caldesmon as a specific marker for smooth muscle
tumors. Comparison with other smooth muscle markers in bone tumors.
Am J Clin Pathol. 113:663–668. 2000.PubMed/NCBI
|
|
16
|
Lawson WE, Polosukhin VV, Zoia O,
Stathopoulos GT, Han W, Plieth D, Loyd JE, Neilson EG and Blackwell
TS: Characterization of fibroblast-specific protein 1 in pulmonary
fibrosis. Am J Respir Crit Care Med. 171:899–907. 2005. View Article : Google Scholar
|
|
17
|
Robertson H, Ali S, McDonnell BJ, Burt AD
and Kirby JA: Chronic renal allograft dysfunction: The role of T
cell-mediated tubular epithelial to mesenchymal cell transition. J
Am Soc Nephrol. 15:390–397. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rygiel KA, Robertson H, Marshall HL,
Pekalski M, Zhao L, Booth TA, Jones DE, Burt AD and Kirby JA:
Epithelial-mesenchymal transition contributes to portal tract
fibrogenesis during human chronic liver disease. Lab Invest.
88:112–123. 2008. View Article : Google Scholar
|
|
19
|
Xie R, Schlumbrecht MP, Shipley GL, Xie S,
Bassett RL Jr and Broaddus RR: S100A4 mediates endometrial cancer
invasion and is a target of TGF-beta1 signaling. Lab Invest.
89:937–947. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ito Y: Oncogenic potential of the RUNX
gene family: ʽoverview'. Oncogene. 23:4198–4208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiao G, Jiang D, Thomas P, Benson MD, Guan
K, Karsenty G and Franceschi RT: MAPK pathways activate and
phosphorylate the osteoblast-specific transcription factor, Cbfa1.
J Biol Chem. 275:4453–4459. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hattori S, Dhar DK, Hara N, Tonomoto Y,
Onoda T, Ono T, Yamanoi A, Tachibana M, Tsuchiya M and Nagasue N:
FR-167653, a selective p38 MAPK inhibitor, exerts salutary effect
on liver cirrhosis through downregulation of Runx2. Lab Invest.
87:591–601. 2007.PubMed/NCBI
|
|
23
|
Ji J, Yu F, Ji Q, Li Z, Wang K, Zhang J,
Lu J, Chen L, E Q, Zeng Y and Ji Y: Comparative proteomic analysis
of rat hepatic stellate cell activation: A comprehensive view and
suppressed immune response. Hepatology. 56:332–349. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rasche A, Al-Hasani H and Herwig R:
Meta-analysis approach identifies candidate genes and associated
molecular networks for type-2 diabetes mellitus. BMC Genomics.
9:3102008. View Article : Google Scholar : PubMed/NCBI
|
